GlassScriptPhysician profile
Melissa A Vance
NPI 1194798603
$14,048.76
in general payments reported to CMS, 2019-2025
33 companies · $2,788 in 2025
The $2,788 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,837 · 2022: $2,222 · 2023: $2,598 · 2024: $4,603 · 2025: $2,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,513 · Consulting Fee: $1,067 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,513.20 |
| Consulting Fee | $1,066.50 |
| Education | $409.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,322.34 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,015.31 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,505.88 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $1,204.21 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Genzyme Corporation | $930.51 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $894.33 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $858.34 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $771.80 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $702.38 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $486.27 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.04 | 2022-2025 | Spevigo, Cyltezo |
| Galderma Laboratories, L.P. | $322.33 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $304.57 | 2021-2024 | Opzelura |
| Pfizer INC. | $278.05 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $269.03 | 2021-2025 | Winlevi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Abbott Laboratories | $104.79 | 2023-2024 | Amplatzer Amulet |
| Epi Health, LLC | $103.00 | 2022 | |
| Dermavant Sciences, INC. | $66.21 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $65.95 | 2023-2025 | Zoryve |
| Mylan Institutional INC. | $54.80 | 2023 | Hulio |
| Qiagen, LLC | $48.85 | 2023-2025 | Quantiferon-Tb Gold Plus |
| Biocon Biologics INC | $48.70 | 2024 | Hulio |
| Organon LLC | $36.93 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $29.03 | 2023 | Ycanth |
| Almirall LLC | $27.88 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $27.13 | 2021-2022 | |
| Medtronic, INC. | $25.12 | 2022 | |
| Lnhc, INC | $17.93 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $15.90 | 2021 | |
| Genentech USA, INC. | $15.53 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.45 | 2021 | |
| Dermira, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.